Good morning :)
$
₹
Vaxcyte Inc

Vaxcyte Inc

PCVX

NASDAQ
Asset Logo

Vaxcyte Inc

PCVX

NASDAQ
$60.373.93% (-2.47)
$
₹
$60.373.93% (-2.47)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $10.0B the stock is ranked 982

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

3.04
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-7.62
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 11 analysts reports

Buy
10 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+94.11%

Earnings Growth

-44.84%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.45
80.45
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.22
27.22
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
30.37
30.37
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 94.11% growth, versus a trailing 3-year CAGR of 8.82%.

2026
Current$60.43Baseline
Analyst Target - 1 year
Target$117.3+94.11%

All values in $

202220232024202520262027$63.40$85.28$107.15Target+94.11%
2026
Current$60.43Baseline
Analyst Target - 1 year
Target$117.3+94.11%

All values in $

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-5.62Baseline
Forecast for Dec 2026
High$-6.19-10.14%
Average$-8.14-44.84%
Low$-9.66-71.89%

All values in $

202120222023202420252026-1.93-3.43-4.13-3.8-5.62Low-71.89%Average-44.84%High-10.14%
2025
Current$-5.62Baseline
Forecast for Dec 2026
High$-6.19-10.14%
Average$-8.14-44.84%
Low$-9.66-71.89%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-212.8
-246.5
-320.6
-284.3
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0000000000
Net Income-95.02-128.70-103.12-137.08-140.71-166.57-212.83-246.50-320.62-284.30
Net Profit Margin----------
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Vaxcyte Inc -3.04-
AbbVie Inc80.4550.450.54
Amgen Inc27.2218.782.45
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare PCVX with any stock or ETF
Compare PCVX with any stock or ETF
Comparing from
PCVX
ABBV
AMGN
Loading...

Frequently asked questions

  1. Vaxcyte Inc (PCVX) share price today is $60.37 as of October 24, 2026 at 1:29 AM IST. The stock touched a day high of $62.54 and a day low of $60.37.

  2. Vaxcyte Inc stock trades on NASDAQ under the ticker symbol PCVX.

  3. Vaxcyte Inc's market capitalization is $9.95B as of October 24, 2026 at 1:29 AM IST.

  4. Vaxcyte Inc's price-to-earnings (P/E) ratio is N/A as of October 24, 2026.

  5. Vaxcyte Inc's price-to-book (P/B) ratio is 3.04 as of October 24, 2026.

  6. Yes, You can buy Vaxcyte Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Vaxcyte Inc shares in three steps: 1. Search Vaxcyte Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Vaxcyte Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Vaxcyte Inc (PCVX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1656 shares at the current price of $60.37.

Loading...